Pre-made Zolbetuximab benchmark antibody ( Whole mAb, anti-CLDN18 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Zolbetuximab benchmark antibody (Whole mAb, anti-CLDN18 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]
| Products Name (INN Index) | Pre-Made Zimberelimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
|---|---|
| INN Name | Zimberelimab |
| Target | PDCD1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Harbin Gloria Pharmaceuticals,WuXi Biologics,Arcus Biosciences,Beijing Cancer Hospital,Guangzhou Gloria Biosciences,Strata Oncology |
| Conditions Approved | Hodgkin's disease |
| Conditions Active | Cervical cancer,Non-small cell lung cancer,Breast cancer,Cancer,Ovarian cancer,Pancreatic cancer,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | PDCD1 |
| Package |
